FibroGen Stock Forum

$FibroGen(FGEN.US)$ Officer Adib Deyaa purchased 22,123 shares of common stock on Jun 12, 2024 at an average price of $1.17 for a total value of $25,883.91.

$FibroGen(FGEN.US)$ See May 7th post! More catalysts possibly to come!

$FibroGen(FGEN.US)$
FibroGen Announces FDA Clearance of Investigational New Drug Application for FG-3165, a Galectin-9 Targeting Monoclonal Antibody, for the Treatment of Patients with Solid Tumors
FibroGen (NASDAQ: FGEN) announced FDA clearance for its Investigational New Drug (IND) application for FG-3165, a monoclonal antibody targeting galectin-9 (Gal9) for treating solid tumors. FG-3165 has shown anti-tumor activity and improved survival in preclinical models and exhibited excellent tol...

$FibroGen(FGEN.US)$
FibroGen Announces Clinical Trial Supply Agreement With Regeneron Pharmaceuticals to Evaluate Fibrogen’s Immuno-Oncology Assets, FG-3165 (Anti-Galectin 9) and FG-3175 (Anti-Ccr8), in Combination With Libtayo® in Upcoming Clinical Trials

$FibroGen(FGEN.US)$ FibroGen Announces FDA Clearance Of Investigational New Drug FG-3165, A Galectin-9 Targeted Monoclonal Antibody For Treating Solid Tumors

$FibroGen(FGEN.US)$ FibroGen Announces Presentation of Positive Interim Data From the Phase 1B Study of FG-3246 (for46) in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostate Cancer (Mcrpc) at the 2024 American Society of Clinical Oncology Annual Meeting

$FibroGen(FGEN.US)$ Upcoming Milestones:
Pamrevlumab
•Topline data from the PanCAN Precision PromiseSM Phase 2/3 study of pamrevlumab in metastatic pancreatic cancer expected in mid-2024, reflecting PanCAN’s updated timing to complete database lock and subsequent analysis of the topline results by the independent Statistical Monitoring Committee.•Topline data from the LAPIS Phase 3 study of pamrevlumab in locally advanced unresectable pancreatic can...